Selective Serotonin Reuptake Inhibitors for Stroke Recovery

Xing Hua; Simiao Wu; Lynn A Legg; Ann-Sofie Rudberg; Maree L Hackett; Russel Tilney; Linnea Lindgren; Mansur A Kutlubaev; Cheng-Fang Hsieh; Amanda J Barugh; Graeme J Hankey; Erik Lundström; Martin Dennis; Gillian E Mead

doi:10.1161/STROKEAHA.121.038149

Selective Serotonin Reuptake Inhibitors for Stroke Recovery

Xing Hua, Simiao Wu, Lynn A Legg, Ann-Sofie Rudberg, Maree L Hackett, Russel Tilney, Linnea Lindgren, Mansur A Kutlubaev, Cheng-Fang Hsieh, Amanda J Barugh, Graeme J Hankey, Erik Lundström, Martin Dennis, Gillian E Mead

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	e426-e428
Journal	Stroke
Volume	53
Issue number	9
DOIs	https://doi.org/10.1161/STROKEAHA.121.038149
Publication status	E-pub ahead of print - 22 Aug 2022

Keywords / Materials (for Non-textual outputs)

Depression/drug therapy
Humans
Serotonin Uptake Inhibitors/pharmacology
Stroke/drug therapy

Access to Document

10.1161/STROKEAHA.121.038149

Cite this

@article{9fa0b43c920c4539b11bf274afb1850d,

title = "Selective Serotonin Reuptake Inhibitors for Stroke Recovery",

keywords = "Depression/drug therapy, Humans, Serotonin Uptake Inhibitors/pharmacology, Stroke/drug therapy",

author = "Xing Hua and Simiao Wu and Legg, {Lynn A} and Ann-Sofie Rudberg and Hackett, {Maree L} and Russel Tilney and Linnea Lindgren and Kutlubaev, {Mansur A} and Cheng-Fang Hsieh and Barugh, {Amanda J} and Hankey, {Graeme J} and Erik Lundstr{\"o}m and Martin Dennis and Mead, {Gillian E}",

note = "Funding Information: This paper is based on a Cochrane Review published in The Cochrane Library 2021, Issue 11 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and The Cochrane Library should be consulted for the most recent version of the review. This updated review was funded by the National Institute for Health Research (NIHR; Cochrane Review Incentive Scheme 2020 [NIHR133254]). Funding Information: Dr Hackett reports grants and contracts for project grant (National Health and Medical Research Council [NHMRC] funding for AFFINITY trial [Assessment of Fluoxetine in Stroke Recovery]), HTA Program (National Institute for Health Research funding for FOCUS [Fluoxetine or Control Under Supervision]), Framework grant (Swedish Research Council funding for EFFECTS [Safety and Efficacy of Fluoxetine on Functional Recovery After Acute Stroke]); all funding received by the author{\textquoteright}s institution. Payment for a fellowship: NHMRC, received by the author{\textquoteright}s institution. Dr Hankey reports grants and contracts: Chief Investigator for the AFFINITY trial, National Health and Medical Research Council of Australia, received by the author{\textquoteright}s institution. Payment or honoraria for lectures, presentations, speakers bureaus, article writing, or educational events: Discussion about antithrombotic therapy to prevent stroke, Medscape, received by the author. Consulting fees: Consulting on design of a possible phase III trial of a new anticoagulant in atrial fibrillation, Janssen Research and Development, received by the author. Payment for participation on a Data Safety Monitoring Board, Advisory Board, or Guideline Panel: Chair or Member of Data Safety Monitoring Committees, of ACI trials of an immune therapies for Alzheimer disease, AC Immune, Lausanne, Switzerland, received by the author; Member of Stroke Prevention Initiative, Bayer, received by the author; Other: Associate Editor of Circulation, American Heart Association, received by the author. Published opinions in medical journals, the public press, broadcast, and social media relevant to the interventions in the work: Publication, Lancet Neurology, AFFINITY trial collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomized, double-blind, placebo-controlled trial. Lancet Neurology 2020;19(8):651–660. doi:10.1016/S1474-4422(20)30207-6. PMID: 32702334; Publication, Stroke. Declaring involvement in eligible studies: Yes, National Health and Medical Research Council of Australia (for AFFINITY trial). Dr Lundstr{\"o}m reports grants and contracts: funding, STROKE-Riksf{\"o}rbundet, received by author{\textquoteright}s institution. Leadership or other fiduciary role in other board, society, committee, or advocacy group: Chief Investigator of the EFFECTS trial, received by author. Declaring involvement in eligible studies: The Swedish Research Council, The Swedish Heart-Lung Fund, The Swedish Brain Fund, STROKE-Riksf{\"o}rbundet, The Swedish Medical Society, Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse. Dr Dennis reports grants and contracts: grants received to perform FOCUS trial—and randomized controlled trial (RCT) which is included in the review, NIHR, Stroke Association, received by the author{\textquoteright}s institution. Dr Mead reports grants and contracts: research grants, HTA NIHR, co-applicant on grants led by Drs Hankey, Hackett, and Lundstr{\"o}m; NIHR incentive award for updating this review, both received by the author{\textquoteright}s institution. Drs Mead, Dennis, Hackett, Lundstr{\"o}m, and Hankey are investigators on the FOCUS trial in the United Kingdom, the AFFINITY trial in Australia, and the EFFECTs trial in Sweden designed to assess the impact of fluoxetine on disability and dependency after stroke. None of these review authors extracted data from these 3 trials. The other authors report no conflicts.",

year = "2022",

month = aug,

day = "22",

doi = "10.1161/STROKEAHA.121.038149",

language = "English",

volume = "53",

pages = "e426--e428",

journal = "Stroke",

issn = "0039-2499",

publisher = "Wolters Kluwer Health",

number = "9",

}

TY - JOUR

T1 - Selective Serotonin Reuptake Inhibitors for Stroke Recovery

AU - Hua, Xing

AU - Wu, Simiao

AU - Legg, Lynn A

AU - Rudberg, Ann-Sofie

AU - Hackett, Maree L

AU - Tilney, Russel

AU - Lindgren, Linnea

AU - Kutlubaev, Mansur A

AU - Hsieh, Cheng-Fang

AU - Barugh, Amanda J

AU - Hankey, Graeme J

AU - Lundström, Erik

AU - Dennis, Martin

AU - Mead, Gillian E

N1 - Funding Information: This paper is based on a Cochrane Review published in The Cochrane Library 2021, Issue 11 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and The Cochrane Library should be consulted for the most recent version of the review. This updated review was funded by the National Institute for Health Research (NIHR; Cochrane Review Incentive Scheme 2020 [NIHR133254]). Funding Information: Dr Hackett reports grants and contracts for project grant (National Health and Medical Research Council [NHMRC] funding for AFFINITY trial [Assessment of Fluoxetine in Stroke Recovery]), HTA Program (National Institute for Health Research funding for FOCUS [Fluoxetine or Control Under Supervision]), Framework grant (Swedish Research Council funding for EFFECTS [Safety and Efficacy of Fluoxetine on Functional Recovery After Acute Stroke]); all funding received by the author’s institution. Payment for a fellowship: NHMRC, received by the author’s institution. Dr Hankey reports grants and contracts: Chief Investigator for the AFFINITY trial, National Health and Medical Research Council of Australia, received by the author’s institution. Payment or honoraria for lectures, presentations, speakers bureaus, article writing, or educational events: Discussion about antithrombotic therapy to prevent stroke, Medscape, received by the author. Consulting fees: Consulting on design of a possible phase III trial of a new anticoagulant in atrial fibrillation, Janssen Research and Development, received by the author. Payment for participation on a Data Safety Monitoring Board, Advisory Board, or Guideline Panel: Chair or Member of Data Safety Monitoring Committees, of ACI trials of an immune therapies for Alzheimer disease, AC Immune, Lausanne, Switzerland, received by the author; Member of Stroke Prevention Initiative, Bayer, received by the author; Other: Associate Editor of Circulation, American Heart Association, received by the author. Published opinions in medical journals, the public press, broadcast, and social media relevant to the interventions in the work: Publication, Lancet Neurology, AFFINITY trial collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomized, double-blind, placebo-controlled trial. Lancet Neurology 2020;19(8):651–660. doi:10.1016/S1474-4422(20)30207-6. PMID: 32702334; Publication, Stroke. Declaring involvement in eligible studies: Yes, National Health and Medical Research Council of Australia (for AFFINITY trial). Dr Lundström reports grants and contracts: funding, STROKE-Riksförbundet, received by author’s institution. Leadership or other fiduciary role in other board, society, committee, or advocacy group: Chief Investigator of the EFFECTS trial, received by author. Declaring involvement in eligible studies: The Swedish Research Council, The Swedish Heart-Lung Fund, The Swedish Brain Fund, STROKE-Riksförbundet, The Swedish Medical Society, Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse. Dr Dennis reports grants and contracts: grants received to perform FOCUS trial—and randomized controlled trial (RCT) which is included in the review, NIHR, Stroke Association, received by the author’s institution. Dr Mead reports grants and contracts: research grants, HTA NIHR, co-applicant on grants led by Drs Hankey, Hackett, and Lundström; NIHR incentive award for updating this review, both received by the author’s institution. Drs Mead, Dennis, Hackett, Lundström, and Hankey are investigators on the FOCUS trial in the United Kingdom, the AFFINITY trial in Australia, and the EFFECTs trial in Sweden designed to assess the impact of fluoxetine on disability and dependency after stroke. None of these review authors extracted data from these 3 trials. The other authors report no conflicts.

PY - 2022/8/22

Y1 - 2022/8/22

KW - Depression/drug therapy

KW - Humans

KW - Serotonin Uptake Inhibitors/pharmacology

KW - Stroke/drug therapy

U2 - 10.1161/STROKEAHA.121.038149

DO - 10.1161/STROKEAHA.121.038149

M3 - Comment/debate

C2 - 35994683

SN - 0039-2499

VL - 53

SP - e426-e428

JO - Stroke

JF - Stroke

IS - 9

ER -